Tempus AI (TEM)

Executive Summary

Tempus AI (NASDAQ: TEM) is a precision medicine company leveraging a proprietary AI platform to analyze the world's largest library of clinical and molecular data, primarily in oncology. Its core business involves aggregating and structuring multimodal data from healthcare partners to enable data-driven clinical decisions and drug discovery. The company's platform-as-a-service model generates recurring revenue from subscriptions and data licensing, while its growing therapeutics pipeline—featuring seven drug candidates across oncology and other indications—offers significant upside potential. Tempus recently initiated a Phase 1 trial for rebecsinib in secondary AML and continues to advance its lead cell therapy programs, A2B530 and A2B694/A2B543, in Phase 1/2 studies for solid tumors. With a strong balance sheet following its 2024 IPO, Tempus is positioned to expand its data network and therapeutic reach. Tempus's investment thesis centers on the convergence of AI-driven data insights and novel therapeutic development. The company's ability to shorten clinical trial timelines and improve success rates through its data library provides a competitive edge in precision oncology. Near-term catalysts include interim data from ongoing trials, potential partnerships with large biopharma for its AI platform, and expansion into new disease areas like cardiology and neurology. However, the company remains unprofitable, with R&D costs offsetting revenue growth. Investors should monitor upcoming data readouts and the pace of commercial adoption of its diagnostic services. The long-term value creation depends on proving the clinical utility of its AI platform and advancing its pipeline through clinical milestones.

Upcoming Catalysts (preview)

• Q4 2026Potential interim data from A2B530 Phase 1/2 trial in solid tumors30% success
• Q2 2027Rebecsinib Phase 1 dose-escalation data in secondary AML25% success
• Q3 2026Strategic partnership for AI platform with major pharma or diagnostic company50% success